EquitySector - HealthcareVery High Risk
Direct
NAV (11-Jul-25)
Returns (Since Inception)
Fund Size
₹332 Cr
Expense Ratio
0.67%
ISIN
INF0QA701AB9
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-1.67%
— (Cat Avg.)
Equity | ₹323.91 Cr | 97.47% |
Others | ₹8.42 Cr | 2.53% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Divi's Laboratories Ltd | Equity | ₹28.8 Cr | 8.67% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹25.07 Cr | 7.55% |
Cipla Ltd | Equity | ₹20.21 Cr | 6.08% |
Apollo Hospitals Enterprise Ltd | Equity | ₹19.81 Cr | 5.96% |
Glenmark Pharmaceuticals Ltd | Equity | ₹11.66 Cr | 3.51% |
Biocon Ltd | Equity | ₹11.65 Cr | 3.51% |
Dr Reddy's Laboratories Ltd | Equity | ₹11.61 Cr | 3.49% |
Piramal Pharma Ltd | Equity | ₹11.09 Cr | 3.34% |
Emcure Pharmaceuticals Ltd | Equity | ₹10.61 Cr | 3.19% |
Abbott India Ltd | Equity | ₹10.6 Cr | 3.19% |
Dr. Lal PathLabs Ltd | Equity | ₹9.36 Cr | 2.82% |
Pfizer Ltd | Equity | ₹9.26 Cr | 2.79% |
Neuland Laboratories Ltd | Equity | ₹9.25 Cr | 2.78% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹8.61 Cr | 2.59% |
Syngene International Ltd | Equity | ₹8.4 Cr | 2.53% |
Torrent Pharmaceuticals Ltd | Equity | ₹8.34 Cr | 2.51% |
Net Receivables / (Payables) | Cash | ₹8.29 Cr | 2.49% |
Fortis Healthcare Ltd | Equity | ₹8.09 Cr | 2.44% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹7.21 Cr | 2.17% |
Rainbow Childrens Medicare Ltd | Equity | ₹7.18 Cr | 2.16% |
Lupin Ltd | Equity | ₹7.03 Cr | 2.12% |
Ipca Laboratories Ltd | Equity | ₹7.02 Cr | 2.11% |
Zydus Wellness Ltd | Equity | ₹6.45 Cr | 1.94% |
Vijaya Diagnostic Centre Ltd | Equity | ₹6.08 Cr | 1.83% |
Medi Assist Healthcare Services Ltd | Equity | ₹5.36 Cr | 1.61% |
Hindustan Unilever Ltd | Equity | ₹4.97 Cr | 1.50% |
Alkem Laboratories Ltd | Equity | ₹4.72 Cr | 1.42% |
Medplus Health Services Ltd | Equity | ₹4.67 Cr | 1.41% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹4.47 Cr | 1.34% |
AstraZeneca Pharma India Ltd | Equity | ₹4.4 Cr | 1.32% |
Emami Ltd | Equity | ₹4.31 Cr | 1.30% |
Jubilant Pharmova Ltd | Equity | ₹4.24 Cr | 1.27% |
Alembic Pharmaceuticals Ltd | Equity | ₹4.15 Cr | 1.25% |
Shaily Engineering Plastics Ltd | Equity | ₹4.13 Cr | 1.24% |
Marico Ltd | Equity | ₹3.83 Cr | 1.15% |
Mankind Pharma Ltd | Equity | ₹3.37 Cr | 1.01% |
Aurobindo Pharma Ltd | Equity | ₹2.84 Cr | 0.85% |
PB Fintech Ltd | Equity | ₹1.79 Cr | 0.54% |
Nestle India Ltd | Equity | ₹1.71 Cr | 0.52% |
Neogen Chemicals Ltd | Equity | ₹1.56 Cr | 0.47% |
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹0.13 Cr | 0.04% |
Large Cap Stocks
30.31%
Mid Cap Stocks
34.27%
Small Cap Stocks
32.89%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹295.16 Cr | 88.82% |
Consumer Defensive | ₹21.27 Cr | 6.40% |
Basic Materials | ₹5.69 Cr | 1.71% |
Financial Services | ₹1.79 Cr | 0.54% |
Standard Deviation
This fund
--
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
1.14
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.10
Higher the better
Since December 2024
Since December 2024
Since December 2024
ISIN INF0QA701AB9 | Expense Ratio 0.67% | Exit Load 1.00% | Fund Size ₹332 Cr | Age 6 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (11-Jul-25)
Returns (Since Inception)
Fund Size
₹332 Cr
Expense Ratio
0.67%
ISIN
INF0QA701AB9
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-1.67%
— (Cat Avg.)
Equity | ₹323.91 Cr | 97.47% |
Others | ₹8.42 Cr | 2.53% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Divi's Laboratories Ltd | Equity | ₹28.8 Cr | 8.67% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹25.07 Cr | 7.55% |
Cipla Ltd | Equity | ₹20.21 Cr | 6.08% |
Apollo Hospitals Enterprise Ltd | Equity | ₹19.81 Cr | 5.96% |
Glenmark Pharmaceuticals Ltd | Equity | ₹11.66 Cr | 3.51% |
Biocon Ltd | Equity | ₹11.65 Cr | 3.51% |
Dr Reddy's Laboratories Ltd | Equity | ₹11.61 Cr | 3.49% |
Piramal Pharma Ltd | Equity | ₹11.09 Cr | 3.34% |
Emcure Pharmaceuticals Ltd | Equity | ₹10.61 Cr | 3.19% |
Abbott India Ltd | Equity | ₹10.6 Cr | 3.19% |
Dr. Lal PathLabs Ltd | Equity | ₹9.36 Cr | 2.82% |
Pfizer Ltd | Equity | ₹9.26 Cr | 2.79% |
Neuland Laboratories Ltd | Equity | ₹9.25 Cr | 2.78% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹8.61 Cr | 2.59% |
Syngene International Ltd | Equity | ₹8.4 Cr | 2.53% |
Torrent Pharmaceuticals Ltd | Equity | ₹8.34 Cr | 2.51% |
Net Receivables / (Payables) | Cash | ₹8.29 Cr | 2.49% |
Fortis Healthcare Ltd | Equity | ₹8.09 Cr | 2.44% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹7.21 Cr | 2.17% |
Rainbow Childrens Medicare Ltd | Equity | ₹7.18 Cr | 2.16% |
Lupin Ltd | Equity | ₹7.03 Cr | 2.12% |
Ipca Laboratories Ltd | Equity | ₹7.02 Cr | 2.11% |
Zydus Wellness Ltd | Equity | ₹6.45 Cr | 1.94% |
Vijaya Diagnostic Centre Ltd | Equity | ₹6.08 Cr | 1.83% |
Medi Assist Healthcare Services Ltd | Equity | ₹5.36 Cr | 1.61% |
Hindustan Unilever Ltd | Equity | ₹4.97 Cr | 1.50% |
Alkem Laboratories Ltd | Equity | ₹4.72 Cr | 1.42% |
Medplus Health Services Ltd | Equity | ₹4.67 Cr | 1.41% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹4.47 Cr | 1.34% |
AstraZeneca Pharma India Ltd | Equity | ₹4.4 Cr | 1.32% |
Emami Ltd | Equity | ₹4.31 Cr | 1.30% |
Jubilant Pharmova Ltd | Equity | ₹4.24 Cr | 1.27% |
Alembic Pharmaceuticals Ltd | Equity | ₹4.15 Cr | 1.25% |
Shaily Engineering Plastics Ltd | Equity | ₹4.13 Cr | 1.24% |
Marico Ltd | Equity | ₹3.83 Cr | 1.15% |
Mankind Pharma Ltd | Equity | ₹3.37 Cr | 1.01% |
Aurobindo Pharma Ltd | Equity | ₹2.84 Cr | 0.85% |
PB Fintech Ltd | Equity | ₹1.79 Cr | 0.54% |
Nestle India Ltd | Equity | ₹1.71 Cr | 0.52% |
Neogen Chemicals Ltd | Equity | ₹1.56 Cr | 0.47% |
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹0.13 Cr | 0.04% |
Large Cap Stocks
30.31%
Mid Cap Stocks
34.27%
Small Cap Stocks
32.89%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹295.16 Cr | 88.82% |
Consumer Defensive | ₹21.27 Cr | 6.40% |
Basic Materials | ₹5.69 Cr | 1.71% |
Financial Services | ₹1.79 Cr | 0.54% |
Standard Deviation
This fund
--
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
1.14
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.10
Higher the better
Since December 2024
Since December 2024
Since December 2024
ISIN INF0QA701AB9 | Expense Ratio 0.67% | Exit Load 1.00% | Fund Size ₹332 Cr | Age 6 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments